|MDACC Study No:||2009-0476 (clinicaltrials.gov NCT No: NCT00960492)|
|Title:||A Phase 1 Dose Finding Study of the Safety and Pharmacokinetics of XL184 Administered Orally in Combination with Temozolomide and Radiation Therapy in the First Line Treatment of Subjects with Malignant Gliomas|
|Principal Investigator:||John DeGroot|
|Treatment Agent:||Temozolomide; XL184|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of XL184 that can be given in combination with temozolomide and radiation
therapy to patients with anaplastic glioma or glioblastoma. The safety of this
combination will also be studied.